Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.45 |
| ▸ | RORC | P51449 | 5/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578200 | 0.94 | CSNK1D (0.47) | CSNK1DCSNK1EHTR4RORCGABRA5 | |
| Trifluoroacetic Acid SCHEMBL4321534 | 0.91 | MAP2K3 (0.51) | HTR4RORCHDAC4HDAC6PPARG | |
| Trifluoroacetic Acid SCHEMBL4339706 | 0.88 | RORC (0.42) | HTR4RORCPPARGCNR1 | |
| Trifluoroacetic Acid SCHEMBL4331249 | 0.87 | GABRA5 (0.40) | CSNK1DCSNK1EHTR4RORCGABRA5 | |
| Trifluoroacetic Acid SCHEMBL4336494 | 0.87 | RORC (0.44) | CSNK1DCSNK1EHTR4RORCPPARG | |
| Trifluoroacetic Acid SCHEMBL4325301 | 0.86 | CNR2 (0.51) | HTR4RORCGABRA5PPARG | |
| SCHEMBL13578153 | 0.83 | MAP2K3 (0.58) | HTR4RORCGABRA5CNR1 | |
| SCHEMBL4324377 | 0.83 | MAP2K3 (0.44) | HTR4RORCCNR1 | |
| Trifluoroacetic Acid SCHEMBL4326422 | 0.83 | L3MBTL1 (0.42) | HTR4RORCPPARG | |
| Trifluoroacetic Acid SCHEMBL4320381 | 0.82 | CNR2 (0.51) | CSNK1DCSNK1EHTR4RORCPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CSNK1D 214/4885CSNK1E 370/4885HTR4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.